Hologic have announced the commercial release of its C-View synthesised 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a tomosynthesis (3D mammography) breast cancer screening exam. C-View software is approved for sale throughout the European Economic Area and in other countries recognising the CE Mark.
For users of Hologic’s 2D plus 3D tomosynthesis breast cancer screening system,C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures.
Dr. Stephen Rose, a board certified radiologist with Houston Breast Imaging, one of the first U.S. radiologists to adopt breast tomosynthesis, stated “Hologic’s synthesised 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic’s combo-mode (2D plus 3D) imaging.”
Hologic is featuring the new algorithm along with the Company’s Selenia Dimensions breast tomosynthesis systemat the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the largest radiology show in the world, taking place at McCormick Place in Chicago November 26 through December 2.
Hologic is the global market leader in breast tomosynthesis (3D mammography) with its Selenia Dimensions platform. In Hologic’s clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed.
